ZEPP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Zepp Health Corp (ZEPP) is not a strong buy at this moment for a beginner investor with a long-term strategy. While there are some positive indicators like revenue growth and potential breakeven in 2026, the company's high debt-to-equity ratio, recent financial losses, and lack of significant trading signals suggest a cautious approach. Holding the stock or waiting for more favorable conditions is recommended.
The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 72.791, and moving averages are converging, suggesting no strong directional trend. The stock is trading near its R1 resistance level of 16.514, with potential upside resistance at 17.718.
Gross margin improved to 40.41%, up 9.72% YoY.
EPS declined by 71.43% YoY. The company's debt-to-equity ratio is 54%, exceeding the typical threshold of 40%. No significant hedge fund or insider trading trends. No recent Congress trading data.
In Q4 2025, revenue increased by 43.03% YoY to $85.165 million. However, net income dropped significantly to -$10.971 million (-70.25% YoY), and EPS fell to -0.04 (-71.43% YoY). Gross margin improved to 40.41%, up 9.72% YoY.
Analysts are optimistic about breakeven in 2026, but achieving this requires a high annual growth rate of 56%. No recent changes in price targets or ratings.
